#EMC2025 #EuropeanMuscleConference
#EMC2025 #EuropeanMuscleConference
Jenni has been awarded an Academy Research Fellowship, which entails a 4-year grant. Jenni shares what the grant will be used for 👇: (1/4)
Thank you to Jenni, Veronica and Marco for organizing the event! 💙
Thank you to Jenni, Veronica and Marco for organizing the event! 💙
@myofinlab.bsky.social
doi.org/10.1177/2214...
First author Milla’s summary of the article:
”The objective of this study was to identify and further investigate the causative genetic variant in a patient with lethal nemaline myopathy.” (1/6)
#MyoBlue
@myofinlab.bsky.social
Another well deserved poster prize for @rostedtfanny.bsky.social 🤩🙌
@myofinlab.bsky.social @folkhalsanresearch.bsky.social
Another well deserved poster prize for @rostedtfanny.bsky.social 🤩🙌
@myofinlab.bsky.social @folkhalsanresearch.bsky.social
▫️ Vilma-Lotta Lehtokari (Docent), Senior scientist
📸 Picture 2: Robert Franko
(1/7)
▫️ Vilma-Lotta Lehtokari (Docent), Senior scientist
📸 Picture 2: Robert Franko
(1/7)
▫️Marco Savarese (Docent), Group leader
Marco got his PhD in Naples in 2014 and moved to Helsinki one year later. Since then, he has been working at the Folkhälsan Research Center. Over the last years, his research activity has addressed three key-challenges … (1/7)
▫️Marco Savarese (Docent), Group leader
Marco got his PhD in Naples in 2014 and moved to Helsinki one year later. Since then, he has been working at the Folkhälsan Research Center. Over the last years, his research activity has addressed three key-challenges … (1/7)
Approximately 5% of the world's population is affected by a rare disease. Rare Disease Day is an important initiative for us, as nearly 90% of neuromuscular disorders are classified as rare diseases. (1/5)
journals.sagepub.com/doi/10.1177/...
First author Vilma-Lotta’s summary of the study: (1/4)
journals.sagepub.com/doi/10.1177/...
First author Vilma-Lotta’s summary of the study: (1/4)